Profile - To The Moon

Tikbalang_

Aim>1incomestreamyeah

Posts · 7Posts · 7
Following · 0Following · 0
Followers · 0Followers · 0

- Tikbalang_Tikbalang_
  ·2023-03-26
  Thanks! If the studies prove this combo is beneficial it will be a boost in the treatment of long covid
  How a cheap diabetes pill could impact sales of Pfizer's COVID antiviral Paxlovid
  With Pfizer saying in January that it expects a huge decline in revenue for its COVID-19 antiviral p
  How a cheap diabetes pill could impact sales of Pfizer's COVID antiviral Paxlovid
  489 Comment
  Like
  Share
  Report
- Tikbalang_Tikbalang_
  ·2023-02-20
  Good
  AI Stocks: The ACTUAL Winners and Losers from the AI Revolution
  In January, media firm Buzzfeed(NASDAQ: BZFD) made headlines after its CEO proposed using ChatGPT to
  AI Stocks: The ACTUAL Winners and Losers from the AI Revolution
  307 Comment
  3
  Share
  Report
- Tikbalang_Tikbalang_
  ·2023-02-20
  One less day for opportunities 🙃
  Reminder: U.S. Market Will Be Closed for Washington's Birthday on Monday, Feb. 20, 2023
  Washington's Birthday (Presidents Day) is around the corner. The U.S. market will be closed on Monda
  Reminder: U.S. Market Will Be Closed for Washington's Birthday on Monday, Feb. 20, 2023
  544 Comment
  14
  Share
  Report
- Tikbalang_Tikbalang_
  ·2022-11-27
  #Legacy in Tiger Brokers Hello Tiger sisters and brothers. I would like toask y'all if it would be great if Tiger Brokers would have Legacy mode onboard? Legacy meaning, if we continue to invest into our retirement and then we happen to die for any reason we can assign a person to take the helm/ replace us. Good idea or not? Would love to hear your thoughts and vote in my poll pls
  730 8
  9
  Share
  Report
- Tikbalang_Tikbalang_
  ·2022-11-09
  Looking forward to a brighter future
  449 Comment
  Like
  Share
  Report
- Tikbalang_Tikbalang_
  ·2022-11-01
  Learning by the day!
  410 Comment
  Like
  Share
  Report
- Tikbalang_Tikbalang_
  ·2022-08-27
  Yay! Slowly but surely! Newbie here
  550 Comment
  Like
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4122719437567292","uuid":"4122719437567292","gmtCreate":1659705682430,"gmtModify":1704447493098,"name":"Tikbalang_","pinyin":"tikbalangtikbalang","introduction":"","introductionEn":"","signature":"Aim>1incomestreamyeah","avatar":"https://community-static.tradeup.com/news/efe523f5362c87cc1f3b856d59a9a667","hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","hatId":"ca_profile_frame_5b7Fd6","hatName":"","vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.09","exceedPercentage":"80.64%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.01","exceedPercentage":"60.07%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9943747424,"gmtCreate":1679781546468,"gmtModify":1679781550924,"author":{"id":"4122719437567292","authorId":"4122719437567292","name":"Tikbalang_","avatar":"https://community-static.tradeup.com/news/efe523f5362c87cc1f3b856d59a9a667","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4122719437567292","authorIdStr":"4122719437567292"},"themes":[],"htmlText":"Thanks! If the studies prove this combo is beneficial it will be a boost in the treatment of long covid","listText":"Thanks! If the studies prove this combo is beneficial it will be a boost in the treatment of long covid","text":"Thanks! If the studies prove this combo is beneficial it will be a boost in the treatment of long covid","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9943747424","repostId":"2322837584","repostType":2,"repost":{"id":"2322837584","pubTimestamp":1679774400,"share":"https://ttm.financial/m/news/2322837584?lang=&edition=fundamental","pubTime":"2023-03-26 04:00","market":"us","language":"en","title":"How a cheap diabetes pill could impact sales of Pfizer's COVID antiviral Paxlovid","url":"https://stock-news.laohu8.com/highlight/detail?id=2322837584","media":"seekingalpha","summary":"With Pfizer saying in January that it expects a huge decline in revenue for its COVID-19 antiviral p","content":"<html><body> <p>With Pfizer saying in January that it expects a huge decline in revenue for its COVID-19 antiviral pill Paxlovid, sales could be impacted in the future by an unlikely medicine: metformin, the long-used drug for diabetes.</p> <p>While combinations of drugs have long been used in clinical practice to produce better efficacy through synergistic results, metformin, one of the first medicines doctors turn to for diabetes, may be a headscratcher. But it shouldn't necessarily be.</p> <p>That's because mounting research indicates that Paxlovid and metformin could improve outcomes related to Long COVID, a chronic illness that could potentially fell millions of those who have gotten COVID.</p> <p>Metformin might also spur use of Paxlovid -- especially if its found to have synergistic effects -- since many individuals are unwilling to take it due to reports of side effects and a COVID rebound effect, though it's unclear if metformin mitigates the rebound.</p> <p>Given its cheap price especially compared to Paxlovid, metformin could eventually become a COVID treatment, even without being taken with Paxlovid. Although research on metformin for COVID looks promising, a great deal more research on the diabetes drug for this indication is needed.</p> <h3><strong>Repurposing Drugs</strong></h3> <p>If metformin eventually achieves wide use as a COVID treatment, it would not be unusual. Many drugs, even after initial approval, are investigated for other purposes, often for conditions completely unrelated to the initial indication, in a process known as repurposing.</p> <p>A good example is finasteride. While the drug was initially approved for overactive bladder under the name Proscar, it later won approval in a different dosage strength as Propecia for hair loss.</p> <p>Before Paxlovid, other antivirals, or monoclonal antibodies were authorized by the US FDA to treat COVID, scientists were feverishly working with a plethora of existing meds to see if any might work against COVID. Among the more notable ones were the antiparastic drug ivermectin and the antidepressant fluvoxamine. Neither has shown conclusive evidence of effectiveness against COVID.</p> <p>Paxlovid is already under investigation in a federal government-funded study of treatments for Long COVID.</p> <h3><strong>The Evidence for Metformin</strong></h3> <p>Although metformin was first discovered in 1922, it wasn't used as a medicine until 1957 in France. Its use in the US didn't begin until 1995. The drug is the most widely used oral therapy for diabetes in the world and the third most prescribed drug in the US, as of 2020.</p> <p>As to why metformin might be effective against COVID, researchers at Northwestern University say that the drug reduces high blood glucose levels, which are linked to poorer COVID; the drug might also decrease the viral cycle of COVID-19; and it might be able to make it more difficult for SARS-CoV-2, the virus that causes COVID, to enter cells.</p> <p>The researchers also noted that metformin was used as a flu treatment in the 1940s and 1950s.</p> <p>The evidence for metformin in COVID so far is promising, but by no means conclusive. A pre-print study in <em>The Lancet</em> published earlier in March headed by researchers at University of Minnesota found that those in the metformin group has a 42% relative decline in the incidence of Long COVID compared to those in the control group. It's important to note, however, that this study has yet to be peer reviewed.</p> <p>The study, which enrolled just over 1.1K people who were overweight or obese, also examined the use of ivermectin and fluvoxamine in preventing long COVID. It did not. </p> <p>\"Future research is needed to understand optimal dosing regimens for preventing Long Covid, whether extended release is effective in persons who have side effects from immediate release metformin, and whether metformin could be used as a treatment for Long Covid,\" the researchers wrote. \"Future research could also assess whether metformin is effective if started during an emergency department visit or hospitalization for Covid-19.\"</p> <p>The same Minnesota researchers previously looked at the three drugs in a similar demographic, those these patients had early symptoms of COVID and weren't hospitalized. Their study, published in the <em>New England Journal of Medicine </em>in August 2022, found that none of the meds led to a decline in emergency department visits, hospitalization, or death compared to a control group. However, those in the metformin group did show possible reduction in a composite endpoint of emergency department visit, hospitalization, or death.</p> <p>Another study that just came out in <em>JAMA Internal Medicine</em> examined nirmatrelvir, one of the two antiviral meds in Paxlovid (the other is ritonavir), in preventing Long COVID symptoms. Researchers took a look at healthcare databases from the US Veterans Administration to find those who had a positive COVID test result and had a least one risk factor to progress to severe disease.</p> <p>Results indicated that nirmatrelvir treatment led to a reduced risk of developing Long COVID symptoms, regardless of vaccination status or history of prior infection, compared to the control group.</p> <p>\"When thinking about whether to use Paxlovid or not, we should be thinking about effectiveness in the acute phase but also effectiveness in reducing the long-term complications from COVID infection,\" co-author Ziyad Al-Aly, chief of research and development at the VA St. Louis Health Care System, told CNN.</p> <p>Despite the promise of Paxlovid and metformin in treating Long COVID, there are still no study results of taking the two drugs together.</p> <h3> <strong>Pfizer's Concerns</strong> </h3> <p>In its Q4 and full-year 2022 earnings report released in January, Pfizer (<span>NYSE:PFE</span>) said that Paxlovid generated ~$19B in sales for the year. However, it warned that in 2023, that figure would decline 58% to $8B.</p> <p>During its earnings call, CEO Albert Bourla conceded that the US government still has an inventory build-up of Paxlovid that will be used up sometime in 2023. In addition, Pfizer (PFE) will likely raise the price of Paxlovid once the COVID public health emergency ends in May. </p> <p>Bourla painted a more optimistic picture for Paxlovid after 2023, however. \"We expect in years 2024 and beyond that the courses sold and used will align closely together within every year.\"</p> <p>While the exec said he sees increased utilization of Paxlovid this year due to more infections, the company has not included any new major non-US or non-China contracts in its Paxlovid sales projections.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How a cheap diabetes pill could impact sales of Pfizer's COVID antiviral Paxlovid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow a cheap diabetes pill could impact sales of Pfizer's COVID antiviral Paxlovid\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-03-26 04:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3951092-metformin-diabetes-could-boost-sales-pfizer-covid-antiviral-paxlovid><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>With Pfizer saying in January that it expects a huge decline in revenue for its COVID-19 antiviral pill Paxlovid, sales could be impacted in the future by an unlikely medicine: metformin, the long-...</p>\n\n<a href=\"https://seekingalpha.com/news/3951092-metformin-diabetes-could-boost-sales-pfizer-covid-antiviral-paxlovid\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1255267561/image_1255267561.jpg","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3951092-metformin-diabetes-could-boost-sales-pfizer-covid-antiviral-paxlovid","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2322837584","content_text":"With Pfizer saying in January that it expects a huge decline in revenue for its COVID-19 antiviral pill Paxlovid, sales could be impacted in the future by an unlikely medicine: metformin, the long-used drug for diabetes. While combinations of drugs have long been used in clinical practice to produce better efficacy through synergistic results, metformin, one of the first medicines doctors turn to for diabetes, may be a headscratcher. But it shouldn't necessarily be. That's because mounting research indicates that Paxlovid and metformin could improve outcomes related to Long COVID, a chronic illness that could potentially fell millions of those who have gotten COVID. Metformin might also spur use of Paxlovid -- especially if its found to have synergistic effects -- since many individuals are unwilling to take it due to reports of side effects and a COVID rebound effect, though it's unclear if metformin mitigates the rebound. Given its cheap price especially compared to Paxlovid, metformin could eventually become a COVID treatment, even without being taken with Paxlovid. Although research on metformin for COVID looks promising, a great deal more research on the diabetes drug for this indication is needed. Repurposing Drugs If metformin eventually achieves wide use as a COVID treatment, it would not be unusual. Many drugs, even after initial approval, are investigated for other purposes, often for conditions completely unrelated to the initial indication, in a process known as repurposing. A good example is finasteride. While the drug was initially approved for overactive bladder under the name Proscar, it later won approval in a different dosage strength as Propecia for hair loss. Before Paxlovid, other antivirals, or monoclonal antibodies were authorized by the US FDA to treat COVID, scientists were feverishly working with a plethora of existing meds to see if any might work against COVID. Among the more notable ones were the antiparastic drug ivermectin and the antidepressant fluvoxamine. Neither has shown conclusive evidence of effectiveness against COVID. Paxlovid is already under investigation in a federal government-funded study of treatments for Long COVID. The Evidence for Metformin Although metformin was first discovered in 1922, it wasn't used as a medicine until 1957 in France. Its use in the US didn't begin until 1995. The drug is the most widely used oral therapy for diabetes in the world and the third most prescribed drug in the US, as of 2020. As to why metformin might be effective against COVID, researchers at Northwestern University say that the drug reduces high blood glucose levels, which are linked to poorer COVID; the drug might also decrease the viral cycle of COVID-19; and it might be able to make it more difficult for SARS-CoV-2, the virus that causes COVID, to enter cells. The researchers also noted that metformin was used as a flu treatment in the 1940s and 1950s. The evidence for metformin in COVID so far is promising, but by no means conclusive. A pre-print study in The Lancet published earlier in March headed by researchers at University of Minnesota found that those in the metformin group has a 42% relative decline in the incidence of Long COVID compared to those in the control group. It's important to note, however, that this study has yet to be peer reviewed. The study, which enrolled just over 1.1K people who were overweight or obese, also examined the use of ivermectin and fluvoxamine in preventing long COVID. It did not.  \"Future research is needed to understand optimal dosing regimens for preventing Long Covid, whether extended release is effective in persons who have side effects from immediate release metformin, and whether metformin could be used as a treatment for Long Covid,\" the researchers wrote. \"Future research could also assess whether metformin is effective if started during an emergency department visit or hospitalization for Covid-19.\" The same Minnesota researchers previously looked at the three drugs in a similar demographic, those these patients had early symptoms of COVID and weren't hospitalized. Their study, published in the New England Journal of Medicine in August 2022, found that none of the meds led to a decline in emergency department visits, hospitalization, or death compared to a control group. However, those in the metformin group did show possible reduction in a composite endpoint of emergency department visit, hospitalization, or death. Another study that just came out in JAMA Internal Medicine examined nirmatrelvir, one of the two antiviral meds in Paxlovid (the other is ritonavir), in preventing Long COVID symptoms. Researchers took a look at healthcare databases from the US Veterans Administration to find those who had a positive COVID test result and had a least one risk factor to progress to severe disease. Results indicated that nirmatrelvir treatment led to a reduced risk of developing Long COVID symptoms, regardless of vaccination status or history of prior infection, compared to the control group. \"When thinking about whether to use Paxlovid or not, we should be thinking about effectiveness in the acute phase but also effectiveness in reducing the long-term complications from COVID infection,\" co-author Ziyad Al-Aly, chief of research and development at the VA St. Louis Health Care System, told CNN. Despite the promise of Paxlovid and metformin in treating Long COVID, there are still no study results of taking the two drugs together.  Pfizer's Concerns  In its Q4 and full-year 2022 earnings report released in January, Pfizer (NYSE:PFE) said that Paxlovid generated ~$19B in sales for the year. However, it warned that in 2023, that figure would decline 58% to $8B. During its earnings call, CEO Albert Bourla conceded that the US government still has an inventory build-up of Paxlovid that will be used up sometime in 2023. In addition, Pfizer (PFE) will likely raise the price of Paxlovid once the COVID public health emergency ends in May.  Bourla painted a more optimistic picture for Paxlovid after 2023, however. \"We expect in years 2024 and beyond that the courses sold and used will align closely together within every year.\" While the exec said he sees increased utilization of Paxlovid this year due to more infections, the company has not included any new major non-US or non-China contracts in its Paxlovid sales projections.","news_type":1},"isVote":1,"tweetType":1,"viewCount":489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9957041967,"gmtCreate":1676844066359,"gmtModify":1676844070323,"author":{"id":"4122719437567292","authorId":"4122719437567292","name":"Tikbalang_","avatar":"https://community-static.tradeup.com/news/efe523f5362c87cc1f3b856d59a9a667","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4122719437567292","authorIdStr":"4122719437567292"},"themes":[],"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9957041967","repostId":"1102735214","repostType":4,"repost":{"id":"1102735214","pubTimestamp":1676779126,"share":"https://ttm.financial/m/news/1102735214?lang=&edition=fundamental","pubTime":"2023-02-19 11:58","market":"us","language":"en","title":"AI Stocks: The ACTUAL Winners and Losers from the AI Revolution","url":"https://stock-news.laohu8.com/highlight/detail?id=1102735214","media":"InvestorPlace","summary":"In January, media firm Buzzfeed(NASDAQ: BZFD) made headlines after its CEO proposed using ChatGPT to","content":"<html><head></head><body><p>In January, media firm <b>Buzzfeed</b>(NASDAQ: <b>BZFD</b>) made headlines after its CEO proposed using ChatGPT to help generate “cultural currency” and “inspired prompts” for his site. The following week, meme stock <b>Helbiz</b>(NASDAQ: <b>HLBZ</b>) would join the frenzy… without any detail on how an e-scooter business benefits from using chatbots.</p><p>Tongues would quickly start wagging.</p><p>“The AI stock mania is reminiscent of other speculative crazes in the world of tech,”wrote<i>CNN’s</i>Paul La Monica. “Remember when crypto-related stocks soared in 2021 and then tanked in 2022? And let’s not forget the epic rise of many dot-com companies in the late 1990s and their subsequent plunge in 2000.”</p><p>Yet, we know that artificial intelligence is here to stay; Mr. La Monica himself later conceded that AI “is no passing fad.” Much like the internet in the late-90s, we <i>know</i> that artificial intelligence creates tangible benefits… even if we’re not sure how to best use it yet.</p><p>That hasn’t stopped investors from unthinkingly rushing in. Shares of Buzzfeed would rise over 100% in the week after its ChatGPT announcement. And Helbiz would spike 250% for a brief period.</p><p>That means it’s more important than ever to separate the companies that <i>claim</i> they will benefit from AI, versus the ones that <i>actually</i> do. The internet of the 1990s couldn’t save outdated businesses from the dustbin of history. And artificial intelligence won’t either.</p><p><b>Chipmakers: Many Winners in the High-Tech World</b></p><p>The most obvious winners of the AI revolution are the chipmakers themselves. No matter which software firm eventually prevails, the top hardware makers must still play a role.</p><p><b>Winners: AI and Analog Chipmakers</b></p><p>The greatest beneficiaries of artificial intelligence are chipmakers that create GPUs (graphical processing units) and ASICs (application-specific integrated circuits) that help train AI models. Most hyped-up alternatives such as Tensor Processing Units (TPUs) and Data Processing Units (DPUs) are usually some combination of these two.</p><p>These types of chips can run multiple processes at once, making them far more powerful than traditional CPUs at training AI algorithms. GPUs are also becoming more scalable, thanks to a new generation of multi-node software.</p><p>As far as the GPU makers themselves, <b>Nvidia</b>(NASDAQ: <b>NVDA</b>) is the leader in the industry. The California-based firm holds a stunning88% market share thanks to a massive R&amp;D budget that can outspend all competitors. It’s a virtuous cycle that allows Nvidia to develop better hardware and more reliable drivers, which in turn sells more products. Analysts expect the GPU maker’s long-term growth rate to top 21%, according to Thomson Reuters.</p><p>However, buying top-dog Nvidia won’t come cheap. The company trades at 65X forward earnings, making it one of the most expensive hardware manufacturers in the world by that metric. Investors know that NVDA is the king, so much of the alpha has already been consumed.</p><p>Fortunately, investors have alternatives. First, the <b>FPGA chip industry</b> (field-programmable gate arrays) is a relatively profitable one that also benefits from AI. These are the low-power chips used to run AI models <i>after</i> they’re trained. Here, firms like <b>Lattice Semiconductor</b>(NASDAQ: <b>LSCC</b>) and Xilinx, a subsidiary of <b>Advanced Micro Devices</b>(NASDAQ: <b><u>AMD</u></b>), are profitable players that can be bought for lower prices than Nvidia. Lattice trades at 46X forward earnings, while AMD trades at 27X.</p><p>Next, investors looking further ahead should also consider <b>analog chipmakers</b>. These firms produce chips that are used in sensors and other IOT (internet of things) devices that connect computers with the outside world. Greater use of AI will naturally increase demand for these chips as applications from self-driving cars to smart homes become commonplace. The analog chip industry is also less competitive (and quite profitable) thanks to years of consolidation. <b>Texas Instruments</b>(NASDAQ: <b>TXN</b>) averages a 31% return on capital invested (ROIC), yet trades for only 21X forward earnings. Smaller competitor <b>Analog Devices</b>(NASDAQ: <b>ADI</b>) has averaged a 20% ROIC and trades at 18X.</p><p>Finally, specialized pick-and-shovel companies such as <b>ASML</b>(NASDAQ: <b>ASML</b>) also stand to gain. ASML, for instance, produces the machines that make AI chips, and can be bought at 33X forward earnings.</p><p><b>Losers: General-Purpose and Commodity Chipmakers</b></p><p>Meanwhile, general-purpose CPU companies will see a demand crunch, at least in relative terms. CPUs have more limited applications in artificial intelligence applications, and the industry’s cyclical nature makes it prone to post-overexpansion hangovers. Analysts estimate that Intel’s revenues will shrink almost 20% this year, and for 2026 profits to be <i>less than half of 2019 levels.</i></p><p>Many commodity chipmakers are in even worse shape. <b>Micron Technology</b>(NASDAQ: <b>MU</b>), a firm that produces commoditized memory chips, has seen analysts cut long-term growth rates to -35.4%, according to data from Thomson Reuters. Though artificial intelligence promises to use <i>more</i> computing power, makers of lower-value chips will mostly see no benefit.</p><p><b>Software Companies: Mostly Good… If You’re High-Tech</b></p><p>It’s still too early to call winners with “generative” AI models. Chatbots — from <b>OpenAI’s</b> ChatGPT to Alphabet’s LaMDA —are relatively neck-and-neck in their problem-solving abilities. And the industry currently has surprisingly low barriers to entry; the internet is a trove of free training data, and talented engineers are quick to switch jobs. It’s a fool’s errand to guess whether <b>Meta Platforms</b>(NASDAQ: <b><u>META</u></b>) or Amazon’s (NASDAQ: <b><u>AMZN</u></b>) AI will come out ahead.</p><p>Nevertheless, winners are already emerging in <i>other</i> industries.</p><p><b>Winners: Data Analytics</b></p><p>The clearest corporate beneficiaries of AI are those that help users analyze, crunch and store data. Many of these companies — such as <b>Salesforce</b>(NASDAQ: <b>CRM</b>) and <b>Workday</b>(NASDAQ: <b>WDAY</b>) — have used existing products to establish a base, and then upsold customers on “value-added” AI products. Workday, for instance, has been able to help employers predict which workers are about to quit…since 2019. And Salesforce’s Einstein now provides salespeople with recommendations for the next best actions when making a sale. Rapid improvements in artificial intelligence will create even more “land and expand” abilities.</p><p>Other firms are more direct. Companies like cloud monitoring firm <b>DataDog</b>(NASDAQ: <b>DDOG</b>) and cybersecurity firm <b>Okta</b>(NASDAQ: <b>OKTA</b>) rely on machine learning to provide any product at all. Without it, their monitoring and authentication services will look much like the legacy systems they’re attempting to replace. And as artificial intelligence improves, products at these next-gen companies will stand out even more relative to legacy products. DataDog and Okta are expected to grow revenues by 32% and 41%, respectively, this year.</p><p><b>Losers: Business Process Outsourcing Firms</b></p><p>On the other hand, AI is squeezing lower-value software companies. And in particular, business process outsourcing (BPO) firms are feeling the heat. Former meme stock <b>Exela Technologies</b>(NASDAQ: <b>XELA</b>) now trades at a near-zero valuation. And Xerox’s BPO spinoff <b>Conduent</b>(NASDAQ: <b>CNDT</b>) has lost over 70% of its market value since spinning off in 2016. These companies specialize in offloading manual tasks to offshore workers, and AI tools are replacing everything from customer service chats to manual data entry.</p><p>Perhaps the only notable exception is <b>Accenture</b>(NYSE: <b>ACN</b>) — a consulting firm that’s long focused on higher-value BPO solutions. But even there, growth is slowing. Analysts expect Accenture’s earnings per share (EPS) growth to decline from the 16% range to single-digits this year.</p><p><b>Digital Media: A Mixed BagWinners: You and Me</b></p><p>In 2021, intense competition between <b>Netflix</b>(NASDAQ: <b>NFLX</b>) and other streaming services sparked “peak TV,” a period of incredible content creation. The number of original, scripted, adult-targeted programs jumped to 559, according to FX Research — straining the wallets of companies from Amazon to <b>Disney</b>(NYSE: <b>DIS</b>)</p><p>A similar gold rush is now happening in generative AI, particularly in digital art and chatbots. High-quality image generators from <b>Midjourney</b> to <b>Stable Diffusion</b> are available to anyone with an internet connection (and enough patience to wait in line). And Microsoft’s $10 billion investment in OpenAI and its ChatGPT is still (mostly) being given away for free to the public. (Google’s Bard might <i>have</i> to be given away, considering its issues).</p><p>The bonanza will last longer than most realize. The cost of running an AI model costs far less than… say… producing a hit TV show. And the competitive cloud industry means that cloud computing firms <i>themselves</i> are the ones using AI chatbots as loss leaders. Online storage might be a commodity. A high-quality chatbot running on it is not.</p><p><b>Losers: Content Creation Sites… And Many NFT Holders</b></p><p>Sadly, advancements in AI won’t help content creation companies — a competitive industry that has already exhausted the benefits of outsourcing. Websites like <i>Forbes</i> already routinely use freelancers in place of full-time staff. Only 10% of Buzzfeed’s staff belong to the NewsGuild labor union.</p><p>The inclusion of AI will only worsen the “race to the bottom” in digital media. Buzzfeed holds no monopoly over ChatGPT usage, so any financial benefit from using the service will be quickly erased by competitors doing the same. Only “AI-content natives” might benefit.</p><p>It’s the same story we saw in apparel in the 2000s with the rise of e-commerce: No clothing brand received an outright advantage, save for online-only companies.</p><p>Then there are NFT holders — investors who splashed out in 2021-2022 to acquire the rights to expensive digital art. Today, AI can create digital pieces by the thousands…and automatically mint them as NFTs if asked. It’s a comeuppance for those who once noted that “lots of NFTs are fairly dumb.”</p><p>Many younger investors might wonder what it was like to invest during the late-1990s tech bubble. With the introduction of AI chatbots and other generative models, these investors don’t have to dream any longer.</p></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AI Stocks: The ACTUAL Winners and Losers from the AI Revolution</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAI Stocks: The ACTUAL Winners and Losers from the AI Revolution\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-19 11:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2023/02/ai-stocks-the-actual-winners-and-losers-from-the-ai-revolution/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In January, media firm Buzzfeed(NASDAQ: BZFD) made headlines after its CEO proposed using ChatGPT to help generate “cultural currency” and “inspired prompts” for his site. The following week, meme ...</p>\n\n<a href=\"https://investorplace.com/2023/02/ai-stocks-the-actual-winners-and-losers-from-the-ai-revolution/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDA":"英伟达","AMD":"美国超微公司"},"source_url":"https://investorplace.com/2023/02/ai-stocks-the-actual-winners-and-losers-from-the-ai-revolution/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102735214","content_text":"In January, media firm Buzzfeed(NASDAQ: BZFD) made headlines after its CEO proposed using ChatGPT to help generate “cultural currency” and “inspired prompts” for his site. The following week, meme stock Helbiz(NASDAQ: HLBZ) would join the frenzy… without any detail on how an e-scooter business benefits from using chatbots.Tongues would quickly start wagging.“The AI stock mania is reminiscent of other speculative crazes in the world of tech,”wroteCNN’sPaul La Monica. “Remember when crypto-related stocks soared in 2021 and then tanked in 2022? And let’s not forget the epic rise of many dot-com companies in the late 1990s and their subsequent plunge in 2000.”Yet, we know that artificial intelligence is here to stay; Mr. La Monica himself later conceded that AI “is no passing fad.” Much like the internet in the late-90s, we know that artificial intelligence creates tangible benefits… even if we’re not sure how to best use it yet.That hasn’t stopped investors from unthinkingly rushing in. Shares of Buzzfeed would rise over 100% in the week after its ChatGPT announcement. And Helbiz would spike 250% for a brief period.That means it’s more important than ever to separate the companies that claim they will benefit from AI, versus the ones that actually do. The internet of the 1990s couldn’t save outdated businesses from the dustbin of history. And artificial intelligence won’t either.Chipmakers: Many Winners in the High-Tech WorldThe most obvious winners of the AI revolution are the chipmakers themselves. No matter which software firm eventually prevails, the top hardware makers must still play a role.Winners: AI and Analog ChipmakersThe greatest beneficiaries of artificial intelligence are chipmakers that create GPUs (graphical processing units) and ASICs (application-specific integrated circuits) that help train AI models. Most hyped-up alternatives such as Tensor Processing Units (TPUs) and Data Processing Units (DPUs) are usually some combination of these two.These types of chips can run multiple processes at once, making them far more powerful than traditional CPUs at training AI algorithms. GPUs are also becoming more scalable, thanks to a new generation of multi-node software.As far as the GPU makers themselves, Nvidia(NASDAQ: NVDA) is the leader in the industry. The California-based firm holds a stunning88% market share thanks to a massive R&D budget that can outspend all competitors. It’s a virtuous cycle that allows Nvidia to develop better hardware and more reliable drivers, which in turn sells more products. Analysts expect the GPU maker’s long-term growth rate to top 21%, according to Thomson Reuters.However, buying top-dog Nvidia won’t come cheap. The company trades at 65X forward earnings, making it one of the most expensive hardware manufacturers in the world by that metric. Investors know that NVDA is the king, so much of the alpha has already been consumed.Fortunately, investors have alternatives. First, the FPGA chip industry (field-programmable gate arrays) is a relatively profitable one that also benefits from AI. These are the low-power chips used to run AI models after they’re trained. Here, firms like Lattice Semiconductor(NASDAQ: LSCC) and Xilinx, a subsidiary of Advanced Micro Devices(NASDAQ: AMD), are profitable players that can be bought for lower prices than Nvidia. Lattice trades at 46X forward earnings, while AMD trades at 27X.Next, investors looking further ahead should also consider analog chipmakers. These firms produce chips that are used in sensors and other IOT (internet of things) devices that connect computers with the outside world. Greater use of AI will naturally increase demand for these chips as applications from self-driving cars to smart homes become commonplace. The analog chip industry is also less competitive (and quite profitable) thanks to years of consolidation. Texas Instruments(NASDAQ: TXN) averages a 31% return on capital invested (ROIC), yet trades for only 21X forward earnings. Smaller competitor Analog Devices(NASDAQ: ADI) has averaged a 20% ROIC and trades at 18X.Finally, specialized pick-and-shovel companies such as ASML(NASDAQ: ASML) also stand to gain. ASML, for instance, produces the machines that make AI chips, and can be bought at 33X forward earnings.Losers: General-Purpose and Commodity ChipmakersMeanwhile, general-purpose CPU companies will see a demand crunch, at least in relative terms. CPUs have more limited applications in artificial intelligence applications, and the industry’s cyclical nature makes it prone to post-overexpansion hangovers. Analysts estimate that Intel’s revenues will shrink almost 20% this year, and for 2026 profits to be less than half of 2019 levels.Many commodity chipmakers are in even worse shape. Micron Technology(NASDAQ: MU), a firm that produces commoditized memory chips, has seen analysts cut long-term growth rates to -35.4%, according to data from Thomson Reuters. Though artificial intelligence promises to use more computing power, makers of lower-value chips will mostly see no benefit.Software Companies: Mostly Good… If You’re High-TechIt’s still too early to call winners with “generative” AI models. Chatbots — from OpenAI’s ChatGPT to Alphabet’s LaMDA —are relatively neck-and-neck in their problem-solving abilities. And the industry currently has surprisingly low barriers to entry; the internet is a trove of free training data, and talented engineers are quick to switch jobs. It’s a fool’s errand to guess whether Meta Platforms(NASDAQ: META) or Amazon’s (NASDAQ: AMZN) AI will come out ahead.Nevertheless, winners are already emerging in other industries.Winners: Data AnalyticsThe clearest corporate beneficiaries of AI are those that help users analyze, crunch and store data. Many of these companies — such as Salesforce(NASDAQ: CRM) and Workday(NASDAQ: WDAY) — have used existing products to establish a base, and then upsold customers on “value-added” AI products. Workday, for instance, has been able to help employers predict which workers are about to quit…since 2019. And Salesforce’s Einstein now provides salespeople with recommendations for the next best actions when making a sale. Rapid improvements in artificial intelligence will create even more “land and expand” abilities.Other firms are more direct. Companies like cloud monitoring firm DataDog(NASDAQ: DDOG) and cybersecurity firm Okta(NASDAQ: OKTA) rely on machine learning to provide any product at all. Without it, their monitoring and authentication services will look much like the legacy systems they’re attempting to replace. And as artificial intelligence improves, products at these next-gen companies will stand out even more relative to legacy products. DataDog and Okta are expected to grow revenues by 32% and 41%, respectively, this year.Losers: Business Process Outsourcing FirmsOn the other hand, AI is squeezing lower-value software companies. And in particular, business process outsourcing (BPO) firms are feeling the heat. Former meme stock Exela Technologies(NASDAQ: XELA) now trades at a near-zero valuation. And Xerox’s BPO spinoff Conduent(NASDAQ: CNDT) has lost over 70% of its market value since spinning off in 2016. These companies specialize in offloading manual tasks to offshore workers, and AI tools are replacing everything from customer service chats to manual data entry.Perhaps the only notable exception is Accenture(NYSE: ACN) — a consulting firm that’s long focused on higher-value BPO solutions. But even there, growth is slowing. Analysts expect Accenture’s earnings per share (EPS) growth to decline from the 16% range to single-digits this year.Digital Media: A Mixed BagWinners: You and MeIn 2021, intense competition between Netflix(NASDAQ: NFLX) and other streaming services sparked “peak TV,” a period of incredible content creation. The number of original, scripted, adult-targeted programs jumped to 559, according to FX Research — straining the wallets of companies from Amazon to Disney(NYSE: DIS)A similar gold rush is now happening in generative AI, particularly in digital art and chatbots. High-quality image generators from Midjourney to Stable Diffusion are available to anyone with an internet connection (and enough patience to wait in line). And Microsoft’s $10 billion investment in OpenAI and its ChatGPT is still (mostly) being given away for free to the public. (Google’s Bard might have to be given away, considering its issues).The bonanza will last longer than most realize. The cost of running an AI model costs far less than… say… producing a hit TV show. And the competitive cloud industry means that cloud computing firms themselves are the ones using AI chatbots as loss leaders. Online storage might be a commodity. A high-quality chatbot running on it is not.Losers: Content Creation Sites… And Many NFT HoldersSadly, advancements in AI won’t help content creation companies — a competitive industry that has already exhausted the benefits of outsourcing. Websites like Forbes already routinely use freelancers in place of full-time staff. Only 10% of Buzzfeed’s staff belong to the NewsGuild labor union.The inclusion of AI will only worsen the “race to the bottom” in digital media. Buzzfeed holds no monopoly over ChatGPT usage, so any financial benefit from using the service will be quickly erased by competitors doing the same. Only “AI-content natives” might benefit.It’s the same story we saw in apparel in the 2000s with the rise of e-commerce: No clothing brand received an outright advantage, save for online-only companies.Then there are NFT holders — investors who splashed out in 2021-2022 to acquire the rights to expensive digital art. Today, AI can create digital pieces by the thousands…and automatically mint them as NFTs if asked. It’s a comeuppance for those who once noted that “lots of NFTs are fairly dumb.”Many younger investors might wonder what it was like to invest during the late-1990s tech bubble. With the introduction of AI chatbots and other generative models, these investors don’t have to dream any longer.","news_type":1},"isVote":1,"tweetType":1,"viewCount":307,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9957043470,"gmtCreate":1676843816490,"gmtModify":1676843820729,"author":{"id":"4122719437567292","authorId":"4122719437567292","name":"Tikbalang_","avatar":"https://community-static.tradeup.com/news/efe523f5362c87cc1f3b856d59a9a667","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4122719437567292","authorIdStr":"4122719437567292"},"themes":[],"htmlText":"One less day for opportunities 🙃","listText":"One less day for opportunities 🙃","text":"One less day for opportunities 🙃","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":14,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9957043470","repostId":"1100725481","repostType":4,"repost":{"id":"1100725481","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1676779312,"share":"https://ttm.financial/m/news/1100725481?lang=&edition=fundamental","pubTime":"2023-02-19 12:01","market":"us","language":"en","title":"Reminder: U.S. Market Will Be Closed for Washington's Birthday on Monday, Feb. 20, 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=1100725481","media":"Tiger Newspress","summary":"Washington's Birthday (Presidents Day) is around the corner. The U.S. market will be closed on Monda","content":"<html><head></head><body><p>Washington&#39;s Birthday (Presidents Day) is around the corner. The U.S. market will be closed on Monday, February 20, 2023. Please take note of the trading arrangements during the holiday period and make the necessary preparations in advance.</p><p><b>About Presidents&#39; Day</b></p><p><b>Presidents&#39; Day</b>, also called <b>Washington&#39;s Birthday</b> at the federal governmental level, is a holiday in the United States celebrated on the third Monday of February to honor all people who served as presidents of the United States and, since 1879, has been the federal holiday honoring George Washington, who led the Continental Army to victory in the American Revolutionary War, presided at the Constitutional Convention of 1787, and was the first U.S. president.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9f9465ca4610b5c38f13638edda32b36\" tg-width=\"1024\" tg-height=\"576\" referrerpolicy=\"no-referrer\"/><span>George Washington with Flag</span></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reminder: U.S. Market Will Be Closed for Washington's Birthday on Monday, Feb. 20, 2023</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReminder: U.S. Market Will Be Closed for Washington's Birthday on Monday, Feb. 20, 2023\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2023-02-19 12:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Washington&#39;s Birthday (Presidents Day) is around the corner. The U.S. market will be closed on Monday, February 20, 2023. Please take note of the trading arrangements during the holiday period and make the necessary preparations in advance.</p><p><b>About Presidents&#39; Day</b></p><p><b>Presidents&#39; Day</b>, also called <b>Washington&#39;s Birthday</b> at the federal governmental level, is a holiday in the United States celebrated on the third Monday of February to honor all people who served as presidents of the United States and, since 1879, has been the federal holiday honoring George Washington, who led the Continental Army to victory in the American Revolutionary War, presided at the Constitutional Convention of 1787, and was the first U.S. president.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9f9465ca4610b5c38f13638edda32b36\" tg-width=\"1024\" tg-height=\"576\" referrerpolicy=\"no-referrer\"/><span>George Washington with Flag</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100725481","content_text":"Washington's Birthday (Presidents Day) is around the corner. The U.S. market will be closed on Monday, February 20, 2023. Please take note of the trading arrangements during the holiday period and make the necessary preparations in advance.About Presidents' DayPresidents' Day, also called Washington's Birthday at the federal governmental level, is a holiday in the United States celebrated on the third Monday of February to honor all people who served as presidents of the United States and, since 1879, has been the federal holiday honoring George Washington, who led the Continental Army to victory in the American Revolutionary War, presided at the Constitutional Convention of 1787, and was the first U.S. president.George Washington with Flag","news_type":1},"isVote":1,"tweetType":1,"viewCount":544,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9966232696,"gmtCreate":1669546042516,"gmtModify":1676538206446,"author":{"id":"4122719437567292","authorId":"4122719437567292","name":"Tikbalang_","avatar":"https://community-static.tradeup.com/news/efe523f5362c87cc1f3b856d59a9a667","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4122719437567292","authorIdStr":"4122719437567292"},"themes":[],"htmlText":"#Legacy in Tiger Brokers Hello Tiger sisters and brothers. I would like toask y'all if it would be great if Tiger Brokers would have Legacy mode onboard? Legacy meaning, if we continue to invest into our retirement and then we happen to die for any reason we can assign a person to take the helm/ replace us.&nbsp; Good idea or not? Would love to hear your thoughts and vote in my poll pls","listText":"#Legacy in Tiger Brokers Hello Tiger sisters and brothers. I would like toask y'all if it would be great if Tiger Brokers would have Legacy mode onboard? Legacy meaning, if we continue to invest into our retirement and then we happen to die for any reason we can assign a person to take the helm/ replace us.&nbsp; Good idea or not? Would love to hear your thoughts and vote in my poll pls","text":"#Legacy in Tiger Brokers Hello Tiger sisters and brothers. I would like toask y'all if it would be great if Tiger Brokers would have Legacy mode onboard? Legacy meaning, if we continue to invest into our retirement and then we happen to die for any reason we can assign a person to take the helm/ replace us. Good idea or not? Would love to hear your thoughts and vote in my poll pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":8,"repostSize":1,"link":"https://ttm.financial/post/9966232696","isVote":2,"tweetType":1,"viewCount":730,"authorTweetTopStatus":1,"verified":2,"vote":{"id":2337,"gmtBegin":1669546042515,"gmtEnd":1670412642000,"type":1,"upper":1,"title":"TB Legacy mode?","choices":[{"id":8923,"sort":1,"name":"Yes","userSize":2,"voted":false},{"id":8924,"sort":2,"name":"No","userSize":0,"voted":false},{"id":8925,"sort":3,"name":"Unsure","userSize":0,"voted":false}]},"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9987456268,"gmtCreate":1667971510054,"gmtModify":1676537992684,"author":{"id":"4122719437567292","authorId":"4122719437567292","name":"Tikbalang_","avatar":"https://community-static.tradeup.com/news/efe523f5362c87cc1f3b856d59a9a667","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4122719437567292","authorIdStr":"4122719437567292"},"themes":[],"htmlText":"Looking forward to a brighter future","listText":"Looking forward to a brighter future","text":"Looking forward to a brighter future","images":[{"img":"https://community-static.tradeup.com/news/f7b48cd3f749faeee17f40c8c951a9d2","width":"1125","height":"1476"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9987456268","isVote":1,"tweetType":1,"viewCount":449,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9985077788,"gmtCreate":1667280859245,"gmtModify":1676537890569,"author":{"id":"4122719437567292","authorId":"4122719437567292","name":"Tikbalang_","avatar":"https://community-static.tradeup.com/news/efe523f5362c87cc1f3b856d59a9a667","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4122719437567292","authorIdStr":"4122719437567292"},"themes":[],"htmlText":"Learning by the day!","listText":"Learning by the day!","text":"Learning by the day!","images":[{"img":"https://community-static.tradeup.com/news/cd5e49d8fcb9a452f2db108469e0c9b0","width":"1125","height":"1476"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9985077788","isVote":1,"tweetType":1,"viewCount":410,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9994154994,"gmtCreate":1661581203822,"gmtModify":1676536546321,"author":{"id":"4122719437567292","authorId":"4122719437567292","name":"Tikbalang_","avatar":"https://community-static.tradeup.com/news/efe523f5362c87cc1f3b856d59a9a667","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4122719437567292","authorIdStr":"4122719437567292"},"themes":[],"htmlText":"Yay! Slowly but surely! Newbie here","listText":"Yay! Slowly but surely! Newbie here","text":"Yay! Slowly but surely! Newbie here","images":[{"img":"https://community-static.tradeup.com/news/e8fe9ae3a2ad7446501e848a9caf7c2b","width":"1125","height":"1476"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9994154994","isVote":1,"tweetType":1,"viewCount":550,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}